Cargando…

MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma

The mitogen‐activated protein kinase (MAPK) pathway plays a central role in colorectal cancers (CRC). In particular, BRAF V600E‐mutant tumors, which represent around 10% of CRCs, are refractory to current therapies. Overexpression and secretion of serine peptidase inhibitor Kazal type 1 (SPINK1) are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Räsänen, Kati, Dang, Kien X., Mustonen, Harri, Ho, Tho H., Lintula, Susanna, Koistinen, Hannu, Stenman, Ulf‐Håkan, Haglund, Caj, Stenman, Jakob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792734/ https://www.ncbi.nlm.nih.gov/pubmed/29193645 http://dx.doi.org/10.1002/1878-0261.12160

Ejemplares similares

Regulation of serine protease inhibitor Kazal type-5 (SPINK5) gene expression in the keratinocytes
por: Le, Ngoc Anh, et al.
Publicado: (2014)

Concomitant Tumor Expression of EGFR and TATI/SPINK1 Associates with Better Prognosis in Colorectal Cancer
por: Koskensalo, Selja, et al.
Publicado: (2013)

The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma
por: Xu, Wen-Hao, et al.
Publicado: (2019)

Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity
por: Ho, Tho H., et al.
Publicado: (2015)

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers
por: Mehner, Christine, et al.
Publicado: (2015)

Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Salmiheimo, Aino, et al.
Publicado: (2016)

Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
por: Nurmi, Anna M., et al.
Publicado: (2021)

Pancreatic cancer survival prediction via inflammatory serum markers
por: Lanki, Mira, et al.
Publicado: (2022)

The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant
por: Buchholz, Ina, et al.
Publicado: (2020)

Evaluation of the expression levels of BRAF(V600E) mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
por: Tran, Tien Viet, et al.
Publicado: (2020)

The Prevalence of Cationic Trypsinogen (PRSS1) and Serine Protease Inhibitor, Kazal Type 1 (SPINK1) Gene Mutations in Polish Patients with Alcoholic and Idiopathic Chronic Pancreatitis
por: Gasiorowska, Anita, et al.
Publicado: (2010)

Tazarotene-Induced Gene 1 (TIG1) Interacts with Serine Protease Inhibitor Kazal-Type 2 (SPINK2) to Inhibit Cellular Invasion of Testicular Carcinoma Cells
por: Shyu, Rong-Yaun, et al.
Publicado: (2019)

Kazal-type serine proteinase inhibitors in the midgut of Phlebotomus papatasi
por: Sigle, Leah Theresa, et al.
Publicado: (2013)

Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer
por: Böckelman, Camilla, et al.
Publicado: (2018)

Identification of Lympho-Epithelial Kazal-Type Inhibitor 2 in Human Skin as a Kallikrein-Related Peptidase 5-Specific Protease Inhibitor
por: Meyer-Hoffert, Ulf, et al.
Publicado: (2009)

Serine Protease Inhibitor Kazal Type 1 (SPINK1) c.194+2T > C Mutation May Predict Long-term Outcome of Endoscopic Treatments in Idiopathic Chronic Pancreatitis
por: Sun, Chang, et al.
Publicado: (2015)

KLK-targeted Therapies for Prostate Cancer
por: Hannu, Koistinen, et al.
Publicado: (2014)

Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine
por: Chen, Yi-Ting, et al.
Publicado: (2022)

Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status
por: Sjöblom, Anni, et al.
Publicado: (2021)

Generation and Analysis of Serine Protease Inhibitor Kazal Type 3-Cre Driver Mice
por: Sakata, Kazuya, et al.
Publicado: (2014)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Ornithine decarboxylase antizyme inhibitor 2 (AZIN2) is a signature of secretory phenotype and independent predictor of adverse prognosis in colorectal cancer
por: Kaprio, Tuomas, et al.
Publicado: (2019)

A deep learning–based algorithm for tall cell detection in papillary thyroid carcinoma
por: Stenman, Sebastian, et al.
Publicado: (2022)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
por: Halila, H., et al.
Publicado: (1987)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Genetic polymorphisms in serine protease inhibitor Kazal-type 5 and risk of atopic dermatitis: A meta-analysis
por: Li, Yunling, et al.
Publicado: (2020)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer
por: Lanki, Mira, et al.
Publicado: (2019)

Identification of Kazal Inhibitor Scaffolds with Identical Canonical Binding Loops and Their Effects on Binding Properties
por: Nagel, Felix, et al.
Publicado: (2023)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

A Kazal-Type Serine Protease Inhibitor from the Defense Gland Secretion of the Subterranean Termite Coptotermes formosanus Shiraki
por: Negulescu, Horia, et al.
Publicado: (2015)

Liver Cancer–Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma
por: Lu, Felix, et al.
Publicado: (2020)

The expression and prognostic value of toll-like receptors (TLRs) in pancreatic cancer patients treated with neoadjuvant therapy
por: Nurmi, Anna Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vm2qote07pjshlcc82182dbg68